Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by scaleyon Apr 20, 2020 9:51pm

109 Views

Post# 30932475

Greetings and salutations longs.

Bad things happen to people like penny. Karma usually takes care of goofs like that. Any who, obviously , it's not anywhere close to being over with Kalytera. We have had silence for a reason. We are not developing a new shovel, it's a drug that is going to save lives. Ffs. I'm expecting back to back awesome news releases soon, really soon. The resident retard can try to bash, but his mental health is affecting his work. Sure glad I got those shares at .015 though! If you're not buying at .02 folks, you will remember not buying at .02. Hang in there , buy more shares, stay healthy, and relax. This puzzle is nearly complete, don't be convinced otherwise. Virtual hug. Most people are good

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario